Zimmer Biomet Holdings, Inc. (ZBH)
| Market Cap | 17.67B -3.7% |
| Revenue (ttm) | 8.41B +9.2% |
| Net Income | 761.20M -16.7% |
| EPS | 3.86 -14.4% |
| Shares Out | 193.46M |
| PE Ratio | 23.68 |
| Forward PE | 10.77 |
| Dividend | $0.96 (1.05%) |
| Ex-Dividend Date | Jun 25, 2026 |
| Volume | 1,543,063 |
| Open | 89.69 |
| Previous Close | 89.23 |
| Day's Range | 89.59 - 91.94 |
| 52-Week Range | 79.12 - 108.29 |
| Beta | 0.46 |
| Analysts | Hold |
| Price Target | 98.05 (+7.35%) |
| Earnings Date | Aug 6, 2026 |
About ZBH
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well a... [Read more]
Financial Performance
In 2025, Zimmer Biomet Holdings's revenue was $8.23 billion, an increase of 7.20% compared to the previous year's $7.68 billion. Earnings were $705.10 million, a decrease of -21.98%.
Financial StatementsAnalyst Summary
According to 27 analysts, the average rating for ZBH stock is "Hold." The 12-month stock price target is $98.05, which is an increase of 7.35% from the latest price.
News
BMO starts Zimmer at Market Perform, says valuation appears attractive
BMO Capital analyst Vik Chopra initiated coverage of Zimmer Biomet (ZBH) with a Market Perform rating and $95 price target Valuation appears attractive, but the firm would like to see…
Zimmer Biomet initiated with a Market Perform at BMO Capital
BMO Capital initiated coverage of Zimmer Biomet (ZBH) with a Market Perform rating and $95 price target
Zimmer Biomet price target lowered to $110 from $120 at Evercore ISI
Evercore ISI lowered the firm’s price target on Zimmer Biomet (ZBH) to $110 from $120 and keeps an Outperform rating on the shares. The firm’s Q2 preview for MedTech, Life…
Medical device maker Zimmer Biomet to hire 500 in 3 years for tech centre in India
Medical device maker Zimmer Biomet plans to hire 500 employees over the next three years for its newly opened technology centre in Bengaluru, a senior executive said, as the U.S.-listed company expa...
Pacira Zimmer to divest iovera degrees to Biomet for $70M upfront
Pacira (PCRX) announced the divestiture of iovera degrees to Zimmer Biomet (ZBH). The iovera degrees system is a FDA-cleared, drug-free medical device that relieves pain via cryoneurolysis-a process w...
Zimmer Biomet Holdings Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
A major U.S. sales channel overhaul is underway, aiming for full transition by end-2027 and improved productivity. Recent product launches and acquisitions are driving growth, while innovation and robotics remain key priorities. Financially, 2026 is a transition year, with mid-single-digit growth targeted beyond.
Zimmer Biomet to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
WARSAW, Ind., June 2, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will ...
Zimmer Biomet price target lowered to $93 from $95 at Citi
Citi lowered the firm’s price target on Zimmer Biomet (ZBH) to $93 from $95 and keeps a Neutral rating on the shares. The firm updated models in the medical technology…
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2026
WARSAW, Ind., May 22, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of...
Zimmer Biomet Holdings Transcript: AGM 2026
The meeting highlighted ongoing transformation, strategic focus on innovation, and operational excellence. Shareholders approved all board proposals except the independent chairman request, while management emphasized capital return, U.S. sales improvement, and S.E.T. growth.
Zimmer Biomet Holdings Transcript: Bank of America Global Healthcare Conference 2026
Q1 2026 delivered strong revenue growth at the top of guidance, with robust U.S. and technology performance. New product launches, especially in Japan, and ongoing sales force transformation are driving future growth. Integration of recent acquisitions and a $1B buyback support a balanced capital strategy.
Zimmer Biomet increases share repurchase program by $250M
Zimmer Biomet (ZBH) announced that it now anticipates repurchasing up to $1B of its common stock during fiscal year 2026, a $250M increase from the company’s prior assumption. Published first…
Zimmer Biomet Increases Share Repurchase Expectations -- Up to $1 Billion by Year End
WARSAW, Ind., May 12, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it now anticipates repurchasing up to $1 billion o...
Zimmer Biomet to Present at the BofA Securities 2026 Health Care Conference
WARSAW, Ind., May 6, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will p...
Zimmer Biomet price target lowered to $92 from $98 at Truist
Truist lowered the firm’s price target on Zimmer Biomet (ZBH) to $92 from $98 and keeps a Hold rating on the shares. The company delivered 2.9% organic revenue growth in…
Zimmer Biomet price target lowered to $95 from $100 at JPMorgan
JPMorgan lowered the firm’s price target on Zimmer Biomet (ZBH) to $95 from $100 and keeps a Neutral rating on the shares.
Zimmer Biomet price target lowered to $105 from $110 at Stifel
Stifel analyst Rick Wise lowered the firm’s price target on Zimmer Biomet (ZBH) to $105 from $110 and keeps a Buy rating on the shares.
Zimmer Biomet price target lowered to $83 from $93 at Canaccord
Canaccord lowered the firm’s price target on Zimmer Biomet (ZBH) to $83 from $93 and keeps a Buy rating on the shares. The firm said they delivered a solid Q1…
Zimmer Biomet price target lowered to $92 from $100 at Baird
Baird lowered the firm’s price target on Zimmer Biomet (ZBH) to $92 from $100 and keeps a Neutral rating on the shares. The firm updated its model ahead of Q1…
Zimmer Biomet price target lowered to $95 from $98 at Citi
Citi analyst Joanne Wuensch lowered the firm’s price target on Zimmer Biomet (ZBH) to $95 from $98 and keeps a Neutral rating on the shares.
Zimmer Biomet price target lowered to $105 from $120 at Citizens
Citizens lowered the firm’s price target on Zimmer Biomet (ZBH) to $105 from $120 and keeps an Outperform rating on the shares. Zimmer Biomet delivered a modest revenue beat and…
Zimmer Biomet price target lowered to $94 from $100 at Barclays
Barclays analyst Matt Miksic lowered the firm’s price target on Zimmer Biomet (ZBH) to $94 from $100 and keeps an Underweight rating on the shares. The firm says the company’s…
Zimmer Biomet Holdings Earnings Call Transcript: Q1 2026
Sales and EPS exceeded expectations, driven by strong technology adoption and new product launches, with guidance for EPS and free cash flow raised for 2026. Strategic investments and sales force transformation are progressing, while recent acquisitions accelerate growth.
Zimmer Biomet Holdings Earnings release: Q1 2026
Zimmer Biomet Holdings released its Q1 2026 earnings on April 28, 2026, summarizing the period's financial results.
Zimmer Biomet Holdings Quarterly report: Q1 2026
Zimmer Biomet Holdings has published its Q1 2026 quarterly earnings report on April 28, 2026.